These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1298 related articles for article (PubMed ID: 34627333)

  • 1. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
    Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
    J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
    Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z
    J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
    Wang D; Wang J; Hu G; Wang W; Xiao Y; Cai H; Jiang L; Meng L; Yang Y; Zhou X; Hong Z; Yao Z; Xiao M; Chen L; Mao X; Zhu L; Wang J; Qiu L; Li C; Zhou J
    Blood; 2021 May; 137(21):2890-2901. PubMed ID: 33512480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
    Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
    Front Immunol; 2021; 12():755866. PubMed ID: 34777368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
    Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
    Front Immunol; 2021; 12():720571. PubMed ID: 34421924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma.
    Li C; Xu J; Luo W; Liao D; Xie W; Wei Q; Zhang Y; Wang X; Wu Z; Kang Y; Zheng J; Xiong W; Deng J; Hu Y; Mei H
    Leukemia; 2024 Jan; 38(1):149-159. PubMed ID: 37848634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
    Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
    Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
    [No Abstract]   [Full Text] [Related]  

  • 8. Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports.
    Xu J; Ming X; Wang C; Xu B; Xiao Y
    Medicine (Baltimore); 2021 May; 100(18):e25784. PubMed ID: 33950974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
    Raje N; Berdeja J; Lin Y; Siegel D; Jagannath S; Madduri D; Liedtke M; Rosenblatt J; Maus MV; Turka A; Lam LP; Morgan RA; Friedman K; Massaro M; Wang J; Russotti G; Yang Z; Campbell T; Hege K; Petrocca F; Quigley MT; Munshi N; Kochenderfer JN
    N Engl J Med; 2019 May; 380(18):1726-1737. PubMed ID: 31042825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.
    Yan L; Qu S; Shang J; Shi X; Kang L; Xu N; Zhu M; Zhou J; Jin S; Yao W; Yao Y; Chen G; Chang H; Zhu X; Yu L; Wu D; Fu C
    Cancer Med; 2021 Jan; 10(2):563-574. PubMed ID: 33356013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
    Zhang L; Shen X; Yu W; Li J; Zhang J; Zhang R; Li J; Chen L
    Ann Med; 2021 Dec; 53(1):1547-1559. PubMed ID: 34459681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study.
    Caillot L; Sleiman E; Lafon I; Chretien ML; Gueneau P; Payssot A; Pedri R; Lakomy D; Bailly F; Guy J; Quenot JP; Avet-Loiseau H; Caillot D
    Transplant Cell Ther; 2024 Jun; 30(6):630.e1-630.e8. PubMed ID: 38458477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
    Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
    J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.
    Gagelmann N; Ayuk F; Atanackovic D; Kröger N
    Eur J Haematol; 2020 Apr; 104(4):318-327. PubMed ID: 31883150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma.
    Reyes KR; Liu YC; Huang CY; Banerjee R; Martin T; Wong SW; Wolf JL; Arora S; Shah N; Chari A; Chung A
    Blood Adv; 2024 May; 8(9):2207-2216. PubMed ID: 38429087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial.
    Shi M; Wang J; Huang H; Liu D; Cheng H; Wang X; Chen W; Yan Z; Sang W; Qi K; Li D; Zhu F; Li Z; Qiao J; Wu Q; Zeng L; Fei X; Gu W; Miao Y; Xu K; Zheng J; Cao J
    Nat Commun; 2024 Apr; 15(1):3371. PubMed ID: 38643278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.
    Li C; Cao W; Que Y; Wang Q; Xiao Y; Gu C; Wang D; Wang J; Jiang L; Xu H; Xu J; Zhou X; Hong Z; Wang N; Huang L; Zhang S; Chen L; Mao X; Xiao M; Zhang W; Meng L; Cao Y; Zhang T; Li J; Zhou J
    Clin Transl Med; 2021 Mar; 11(3):e346. PubMed ID: 33784005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.
    Duan D; Wang K; Wei C; Feng D; Liu Y; He Q; Xu X; Wang C; Zhao S; Lv L; Long J; Lin D; Zhao A; Fang B; Jiang J; Tang S; Gao J
    Front Immunol; 2021; 12():609421. PubMed ID: 33767695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.